TC Biopharm (Holdings) Plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodifie… Read more
TC Biopharm (Holdings) Plc (TCBWF) - Net Assets
Latest net assets as of June 2024: $2.00 Million USD
Based on the latest financial reports, TC Biopharm (Holdings) Plc (TCBWF) has net assets worth $2.00 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.87 Million) and total liabilities ($4.87 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.00 Million |
| % of Total Assets | 29.17% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 349.26 |
TC Biopharm (Holdings) Plc - Net Assets Trend (2020–2024)
This chart illustrates how TC Biopharm (Holdings) Plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TC Biopharm (Holdings) Plc (2020–2024)
The table below shows the annual net assets of TC Biopharm (Holdings) Plc from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.01 Million | +12.08% |
| 2023-12-31 | $2.69 Million | +710.60% |
| 2022-12-31 | $331.26K | +102.00% |
| 2021-12-31 | $-16.56 Million | -394.73% |
| 2020-12-31 | $-3.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to TC Biopharm (Holdings) Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3266967200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $55.57 Million | 1846.37% |
| Total Equity | $3.01 Million | 100.00% |
TC Biopharm (Holdings) Plc Competitors by Market Cap
The table below lists competitors of TC Biopharm (Holdings) Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lustrum Minerals Limited
AU:LRM
|
$21.87 Million |
|
Bayrak EBT Taban Sanayi ve Ticaret Anonim Sirketi
IS:BAYRK
|
$21.88 Million |
|
Beaconsmind AG
PA:MLBMD
|
$21.90 Million |
|
Pan Global Resources Inc.
OTCQX:PGZFF
|
$21.91 Million |
|
Kokuyo Camlin Limited
NSE:KOKUYOCMLN
|
$21.86 Million |
|
Bayu Buana Tbk
JK:BAYU
|
$21.86 Million |
|
Singsongholdin
KO:006880
|
$21.85 Million |
|
CALGRO M3 HLDGS RC-00001
F:5C2
|
$21.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TC Biopharm (Holdings) Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,685,230 to 3,009,623, a change of 324,393 (12.1%).
- Net loss of 12,154,030 reduced equity.
- New share issuances of 819,635 increased equity.
- Other factors increased equity by 11,658,788.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.15 Million | -403.84% |
| Share Issuances | $819.63K | +27.23% |
| Other Changes | $11.66 Million | +387.38% |
| Total Change | $- | 12.08% |
Book Value vs Market Value Analysis
This analysis compares TC Biopharm (Holdings) Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.15x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-8.56 | $0.00 | x |
| 2021-12-31 | $-33.88 | $0.00 | x |
| 2022-12-31 | $0.15 | $0.00 | x |
| 2023-12-31 | $0.10 | $0.00 | x |
| 2024-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TC Biopharm (Holdings) Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -403.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.77x
- Recent ROE (-403.84%) is below the historical average (-204.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -275.84% | 0.27x | 0.00x | $-5.12 Million |
| 2021 | 0.00% | -686.12% | 0.25x | 0.00x | $-11.92 Million |
| 2022 | -396.54% | -34.17% | 0.34x | 34.09x | $-1.35 Million |
| 2023 | -219.98% | 0.00% | 0.00x | 3.33x | $-6.18 Million |
| 2024 | -403.84% | 0.00% | 0.00x | 2.77x | $-12.45 Million |
Industry Comparison
This section compares TC Biopharm (Holdings) Plc's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TC Biopharm (Holdings) Plc (TCBWF) | $2.00 Million | 0.00% | 2.43x | $21.87 Million |
| Abcam plc (ABCZF) | $726.90 Million | -1.17% | 0.45x | $5.00 Billion |
| Able View Global Inc. Warrant (ABLVW) | $11.42 Million | 85.41% | 3.81x | $277.93K |
| Above Food Ingredients Inc. Warrants (ABVEW) | $199.86 Million | -2.89% | 0.00x | $6.25 Million |
| Adamas Trust, Inc. (ADAMG) | $2.43 Billion | 7.94% | 1.33x | $2.09 Billion |
| ADS-TEC ENERGY PLC Warrant (ADSEW) | $33.92 Million | -162.39% | 2.67x | $10.06 Million |
| Alliance Entertainment Holding Corporation Warrants (AENTW) | $52.92 Million | 10.13% | 4.23x | $2.29 Million |
| Forafric Global PLC Warrants (AFRIW) | $5.32 Million | -457.58% | 45.29x | $2.67 Million |
| Centurion Acquisition Corp. Warrant (ALFUW) | $282.84 Million | 1.97% | 0.05x | $4.81 Million |
| Alliance Trust PLC (ALITF) | $4.04 Billion | 10.04% | 0.29x | $112.87K |
| Alvotech Warrant (ALVOW) | $-564.42 Million | 0.00% | 0.00x | $35.01 Million |